{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T21:59:07Z","timestamp":1783547947324,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-01582-2","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:15:23Z","timestamp":1737609323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["JAK inhibitors: a new choice for diabetes mellitus?"],"prefix":"10.1186","volume":"17","author":[{"given":"Mengjun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"Supplement_1","key":"1582_CR1","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.2337\/dc22-S006","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. Glycemic targets: Standards of Medical Care in Diabetes\u20142022. Diabetes Care. 2022;45(Supplement_1):S83\u201396.","journal-title":"Diabetes Care"},{"issue":"21","key":"1582_CR2","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips RL, Wang Y, Cheon H, et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell. 2022;185(21):3857\u201376.","journal-title":"Cell"},{"issue":"1","key":"1582_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","volume":"16","author":"WJ Leonard","year":"1998","unstructured":"Leonard WJ, O\u2019Shea JJ. JAKS AND STATS: biological implications. Annu Rev Immunol. 1998;16(1):293\u2013322.","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"1582_CR4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1242\/jcs.00963","volume":"117","author":"JS Rawlings","year":"2004","unstructured":"Rawlings JS, Rosler KM, Harrison DA. The JAK\/STAT signaling pathway. J Cell Sci. 2004;117(8):1281\u20133.","journal-title":"J Cell Sci"},{"issue":"10302","key":"1582_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, et al. Current and future status of JAK inhibitors. Lancet. 2021;398(10302):803\u201316.","journal-title":"The Lancet"},{"issue":"1","key":"1582_CR6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.dsx.2018.10.008","volume":"13","author":"SY Tan","year":"2019","unstructured":"Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr. 2019;13(1):364\u201372.","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"1582_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12916-020-01688-6","volume":"18","author":"H Kolb","year":"2020","unstructured":"Kolb H, Kempf K, R\u00f6hling M, et al. Insulin: too much of a good thing is bad. BMC Med. 2020;18(1):224.","journal-title":"BMC Med"},{"issue":"04","key":"1582_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1055\/a-2239-2668","volume":"56","author":"J Taneera","year":"2024","unstructured":"Taneera J, Saber-Ayad MM. Preservation of \u03b2-cells as a therapeutic strategy for diabetes. Horm Metab Res. 2024;56(04):261\u201371.","journal-title":"Horm Metab Res"},{"issue":"1","key":"1582_CR9","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","volume":"3","author":"A Katsarou","year":"2017","unstructured":"Katsarou A, Gudbj\u00f6rnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3(1):17016.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1582_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-023-01847-y","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Teplizumab: first approval. Drugs. 2023;83(5):439\u201345.","journal-title":"Drugs"},{"issue":"12","key":"1582_CR11","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1080\/13543784.2022.2022119","volume":"30","author":"C Mignogna","year":"2021","unstructured":"Mignogna C, Maddaloni E, D\u2019Onofrio L, et al. Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes. Expert Opin Investig Drugs. 2021;30(12):1209\u201319.","journal-title":"Expert Opin Investig Drugs"},{"issue":"15","key":"1582_CR12","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1056\/NEJMc2022226","volume":"383","author":"NS Chaimowitz","year":"2020","unstructured":"Chaimowitz NS, Ebenezer SJ, Hanson IC, et al. STAT1 gain of function, type 1 diabetes, and reversal with JAK inhibition. N Engl J Med. 2020;383(15):1494\u20136.","journal-title":"N Engl J Med"},{"key":"1582_CR13","first-page":"1","volume":"2019","author":"Y Fujita","year":"2019","unstructured":"Fujita Y, Nawata M, Nagayasu A, et al. Fifty-two-week results of clinical and imaging assessments of a patient with rheumatoid arthritis complicated by systemic sclerosis with interstitial pneumonia and type 1 diabetes despite multiple disease-modifying antirheumatic drug therapy that was successfully treated with baricitinib: a novel case report. Case Rep Rheumatol. 2019;2019:1\u20135.","journal-title":"Case Rep Rheumatol"},{"issue":"8","key":"1582_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s10875-020-00864-w","volume":"40","author":"O Wegehaupt","year":"2020","unstructured":"Wegehaupt O, Muckenhaupt T, Johnson MB, et al. Ruxolitinib controls lymphoproliferation and diabetes in a STAT3-GOF patient. J Clin Immunol. 2020;40(8):1207\u201310.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1582_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13075-023-03249-7","volume":"26","author":"C Di Muzio","year":"2024","unstructured":"Di Muzio C, Di Cola I, Shariat Panahi A, et al. The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study. Arthritis Res Ther. 2024;26(1):14.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1582_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/medicina60030360","volume":"60","author":"C Martinez-Molina","year":"2024","unstructured":"Martinez-Molina C, Diaz-Torne C, Park HS, et al. Tofacitinib and baricitinib in type 2 diabetic patients with rheumatoid arthritis. Medicina. 2024;60(3):360.","journal-title":"Medicina"},{"key":"1582_CR17","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/db16-1250","volume":"66","author":"PM Trivedi","year":"2017","unstructured":"Trivedi PM, Graham KL, Scott NA, et al. Repurposed JAK1\/JAK2 inhibitor reverses established autoimmune insulitis in NOD mice. Diabetes. 2017;66:1650\u201360.","journal-title":"Diabetes"},{"issue":"1","key":"1582_CR18","doi-asserted-by":"publisher","first-page":"e13688","DOI":"10.1111\/cts.13688","volume":"17","author":"M-EF Mohamed","year":"2024","unstructured":"Mohamed M-EF, Bhatnagar S, Parmentier JM, et al. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1):e13688.","journal-title":"Clin Transl Sci"},{"key":"1582_CR19","first-page":"58843","volume":"11","author":"M-S Lee","year":"2020","unstructured":"Lee M-S, Wong FS, Kim S, et al. The JAK1 selective inhibitor ABT 317 blocks signaling through interferon-\u03b3 and common \u03b3 chain cytokine receptors to reverse autoimmune diabetes in NOD mice. Front Immunol. 2020;11:58843.","journal-title":"Front Immunol"},{"issue":"6","key":"1582_CR20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.2174\/187152007784111304","volume":"7","author":"FM Uckun","year":"2007","unstructured":"Uckun FM, Vassilev A, Dibirdik I, et al. Targeting JAK3 tyrosine kinase-linked signal transduction pathways with rationally-designed inhibitors. Anticancer Agents Med Chem. 2007;7(6):612\u201323.","journal-title":"Anticancer Agents Med Chem"},{"issue":"6","key":"1582_CR21","first-page":"1569","volume":"5","author":"EA Sudbeck","year":"1999","unstructured":"Sudbeck EA, Liu X-P, Narla RK, et al. Structure-based design of specific inhibitors of janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999;5(6):1569\u201382.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1582_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1521-6616(02)00049-9","volume":"106","author":"M Cetkovic-Cvrlje","year":"2003","unstructured":"Cetkovic-Cvrlje M, Dragt AL, Vassilev A, et al. Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Clin Immunol. 2003;106(3):213\u201325.","journal-title":"Clin Immunol"},{"issue":"4","key":"1582_CR23","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/ijms24043391","volume":"24","author":"L Rusi\u00f1ol","year":"2023","unstructured":"Rusi\u00f1ol L, Puig L. Tyk2 targeting in immune-mediated inflammatory diseases. Int J Mol Sci. 2023;24(4):3391.","journal-title":"Int J Mol Sci"},{"key":"1582_CR24","doi-asserted-by":"publisher","first-page":"1263926","DOI":"10.3389\/fimmu.2023.1263926","volume":"14","author":"RS Dos Santos","year":"2023","unstructured":"Dos Santos RS, Guzman-Llorens D, Perez-Serna AA, et al. Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-\u03b2H1 \u03b2-cells against proinflammatory insults. Front Immunol. 2023;14:1263926.","journal-title":"Front Immunol"},{"key":"1582_CR25","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","volume":"389","author":"M Waibel","year":"2023","unstructured":"Waibel M, Wentworth JM, So M, et al. Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes. N Engl J Med. 2023;389:2140\u201350.","journal-title":"N Engl J Med"},{"key":"1582_CR26","doi-asserted-by":"publisher","first-page":"117045","DOI":"10.1016\/j.lfs.2019.117045","volume":"239","author":"HY Bako","year":"2019","unstructured":"Bako HY, Ibrahim MA, Isah MS, et al. Inhibition of JAK-STAT and NF-\u03baB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes. Life Sci. 2019;239:117045.","journal-title":"Life Sci"},{"issue":"Supplement_2","key":"1582_CR27","doi-asserted-by":"publisher","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","volume":"60","author":"B Clarke","year":"2021","unstructured":"Clarke B, Yates M, Adas M, et al. The safety of JAK-1 inhibitors. Rheumatology. 2021;60(Supplement_2):ii24\u201330.","journal-title":"Rheumatology"},{"issue":"1","key":"1582_CR28","doi-asserted-by":"publisher","first-page":"15302","DOI":"10.1038\/s41598-019-51636-5","volume":"9","author":"APR Sutherland","year":"2019","unstructured":"Sutherland APR, Graham KL, Papadimitriou M, et al. IL-21 regulates SOCS1 expression in autoreactive CD8+ T cells but is not required for acquisition of CTL activity in the islets of non-obese diabetic mice. Sci Rep. 2019;9(1):15302.","journal-title":"Sci Rep"},{"issue":"6","key":"1582_CR29","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1016\/j.ajpath.2011.02.015","volume":"178","author":"KL Graham","year":"2011","unstructured":"Graham KL, Krishnamurthy B, Fynch S, et al. Autoreactive cytotoxic T lymphocytes acquire higher expression of cytotoxic effector markers in the islets of NOD mice after priming in pancreatic lymph nodes. Am J Pathol. 2011;178(6):2716\u201325.","journal-title":"Am J Pathol"},{"issue":"4","key":"1582_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri1052","volume":"3","author":"KS Schluns","year":"2003","unstructured":"Schluns KS, Lefran\u00e7ois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003;3(4):269\u201379.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"1582_CR31","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.4049\/jimmunol.1201730","volume":"190","author":"APR Sutherland","year":"2013","unstructured":"Sutherland APR, Joller N, Michaud M, et al. IL-21 promotes CD8+ CTL activity via the transcription factor T-bet. J Immunol. 2013;190(8):3977\u201384.","journal-title":"J Immunol"},{"issue":"3","key":"1582_CR32","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.4049\/jimmunol.134.3.1644","volume":"134","author":"F Erard","year":"1985","unstructured":"Erard F, Corthesy P, Nabholz M, et al. Interleukin 2 is both necessary and sufficient for the growth and differentiation of Lectin-stimulated cytolytic T lymphocyte precursors. J Immunol. 1985;134(3):1644\u201352.","journal-title":"J Immunol"},{"issue":"11","key":"1582_CR33","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1007\/s00125-016-4067-4","volume":"59","author":"SJ Richardson","year":"2016","unstructured":"Richardson SJ, Rodriguez-Calvo T, Gerling IC, et al. Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia. 2016;59(11):2448\u201358.","journal-title":"Diabetologia"},{"key":"1582_CR34","doi-asserted-by":"publisher","first-page":"1270325","DOI":"10.3389\/fendo.2023.1270325","volume":"14","author":"MA Russell","year":"2023","unstructured":"Russell MA, Richardson SJ, Morgan NG. The role of the interferon\/JAK-STAT axis in driving islet HLA-I hyperexpression in type 1 diabetes. Front Endocrinol. 2023;14:1270325.","journal-title":"Front Endocrinol"},{"issue":"5","key":"1582_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2174\/1566524020666201015144702","volume":"21","author":"M Sopjani","year":"2021","unstructured":"Sopjani M, Morina R, Uka V, et al. JAK2-mediated intracellular signaling. Curr Mol Med. 2021;21(5):417\u201325.","journal-title":"Curr Mol Med"},{"key":"1582_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/bs.podrm.2018.11.003","volume":"44","author":"AA Abdelgalil","year":"2019","unstructured":"Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI. Sorafenib. Profiles Drug Subst Excip Relat Methodol. 2019;44:239\u201366.","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"2","key":"1582_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/84732","volume":"27","author":"L Adorini","year":"2001","unstructured":"Adorini L. Interleukin 12 and autoimmune diabetes. Nat Genet. 2001;27(2):131\u20132.","journal-title":"Nat Genet"},{"issue":"2","key":"1582_CR38","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s10753-012-9555-1","volume":"36","author":"Z Ahmadi","year":"2013","unstructured":"Ahmadi Z, Arababadi MK, Hassanshahi G. CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus. Inflammation. 2013;36(2):364\u201371.","journal-title":"Inflammation"},{"issue":"1","key":"1582_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"1582_CR40","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.tips.2004.09.008","volume":"25","author":"AC Papageorgiou","year":"2004","unstructured":"Papageorgiou AC, Wikman LEK. Is JAK3 a new drug target for Immunomodulation-based therapies? Trends Pharmacol Sci. 2004;25(11):558\u201362.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"1582_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1006\/clin.1994.1068","volume":"71","author":"KJ Pennline","year":"1994","unstructured":"Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol. 1994;71(2):169\u201375.","journal-title":"Clin Immunol Immunopathol"},{"issue":"9","key":"1582_CR42","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.4049\/jimmunol.158.9.4507","volume":"158","author":"XX Zheng","year":"1997","unstructured":"Zheng XX, Steele AW, Hancock WW, et al. A noncytolytic IL-10\/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol (Baltimore, Md: 1950). 1997;158(9):4507\u201313.","journal-title":"J Immunol (Baltimore, Md.: 1950)"},{"issue":"4","key":"1582_CR43","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/cmi.2012.20","volume":"9","author":"M Cetkovic-Cvrlje","year":"2012","unstructured":"Cetkovic-Cvrlje M, Olson M, Ghate K. Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-\u03b2 by CD4+ T cells. Cell Mol Immunol. 2012;9(4):350\u201360.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"1582_CR44","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","volume":"11","author":"A Chimalakonda","year":"2021","unstructured":"Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with janus kinase 1\/2\/3 inhibitors. Dermatol Ther. 2021;11(5):1763\u201376.","journal-title":"Dermatol Ther"},{"issue":"502","key":"1582_CR45","doi-asserted-by":"publisher","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):eaaw1736.","journal-title":"Sci Transl Med"},{"issue":"8573","key":"1582_CR46","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(87)91128-7","volume":"330","author":"K Foulis Alan","year":"1987","unstructured":"Foulis Alan K, Farquharson Maura A, Meager A. Immunoreactive \u03b1-interferon in insulin-secreting \u03b2 cells in type 1 diabetes mellitus. Lancet. 1987;330(8573):1423\u20137.","journal-title":"The Lancet"},{"issue":"4","key":"1582_CR47","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s00125-016-4201-3","volume":"60","author":"L Marroqui","year":"2017","unstructured":"Marroqui L, Dos Santos RS, Op De Beeck A, et al. Interferon-\u03b1 mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes. Diabetologia. 2017;60(4):656\u201367.","journal-title":"Diabetologia"},{"issue":"1","key":"1582_CR48","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1038\/s41467-020-16327-0","volume":"11","author":"ML Colli","year":"2020","unstructured":"Colli ML, Ramos-Rodr\u00edguez M, Nakayasu ES, et al. An integrated multi-omics approach identifies the landscape of interferon-\u03b1-mediated responses of human pancreatic beta cells. Nat Commun. 2020;11(1):2584.","journal-title":"Nat Commun"},{"issue":"1","key":"1582_CR49","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1038\/s41467-022-34069-z","volume":"13","author":"V Chandra","year":"2022","unstructured":"Chandra V, Ibrahim H, Halliez C, et al. The type 1 diabetes gene TYK2 regulates \u03b2-cell development and its responses to interferon-\u03b1. Nat Commun. 2022;13(1):6363.","journal-title":"Nat Commun"},{"issue":"1","key":"1582_CR50","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, Van Der Heijde D, Chen Y-C. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheumatic Dis. 2017;76(1):88\u201395.","journal-title":"Ann Rheumatic Dis"},{"issue":"5","key":"1582_CR51","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","volume":"33","author":"K Phan","year":"2019","unstructured":"Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1582_CR52","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795\u2013807.","journal-title":"N Engl J Med"},{"issue":"9","key":"1582_CR53","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","volume":"83","author":"E Freitas","year":"2023","unstructured":"Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023;83(9):761\u201370.","journal-title":"Drugs"},{"issue":"11","key":"1582_CR54","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","volume":"18","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012;18(11):3008\u201314.","journal-title":"Clin Cancer Res"},{"key":"1582_CR55","unstructured":"Haq M, Adnan G. Ruxolitinib. In: StatPearls [Internet]. StatPearls Publishing; 2023."},{"issue":"2","key":"1582_CR56","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bbmt.2018.09.003","volume":"25","author":"B Modi","year":"2019","unstructured":"Modi B, Hernandez-Henderson M, Yang D, et al. Ruxolitinib as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2019;25(2):265\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"1582_CR57","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs. 2017;77(18):1987\u20132001.","journal-title":"Drugs"},{"issue":"8","key":"1582_CR58","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12325-013-0047-y","volume":"30","author":"C Rakieh","year":"2013","unstructured":"Rakieh C, Conaghan PG. Tofacitinib for treatment of rheumatoid arthritis. Adv Ther. 2013;30(8):713\u201326.","journal-title":"Adv Ther"},{"issue":"9","key":"1582_CR59","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","volume":"14","author":"A Berekmeri","year":"2018","unstructured":"Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719\u201330.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"1582_CR60","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","volume":"14","author":"A Berekmeri","year":"2018","unstructured":"Berekmeri A, Mahmood F, Wittmann M, et al. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719\u201330.","journal-title":"Expert Rev Clin Immunol"},{"issue":"18","key":"1582_CR61","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723\u201336.","journal-title":"N Engl J Med"},{"issue":"11","key":"1582_CR62","first-page":"e48258","volume":"15","author":"NT Jones","year":"2023","unstructured":"Jones NT, Keller CL, Abadie RB, et al. Safety and Effectiveness of tofacitinib in treating polyarticular course juvenile idiopathic arthritis. Cureus. 2023;15(11):e48258.","journal-title":"Cureus"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01582-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01582-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01582-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T17:07:46Z","timestamp":1737652066000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01582-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01582-2","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript and the submission to this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}